E. Ohman J or Asset Management AB Has $4.83 Million Stake in Natera, Inc. $NTRA

Key Points

• E. Ohman J or Asset Management AB sold 2,700 shares of Natera, Inc., reducing its stake by 8.6% and leaving them with 28,563 shares worth approximately $4.8 million.
• Insider trading activity included the CFO selling 3,045 shares and the CEO selling 6,092 shares, indicating a decrease in ownership for both executives.
• Equities analysts have a positive outlook on Natera with an average target price of $194.00 and multiple analysts rating it as a "Buy".

E. Ohman J or Asset Management AB lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,563 shares of the medical research company's stock after selling 2,700 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Natera were worth $4,825,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of NTRA. Price T Rowe Associates Inc. MD lifted its stake in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares in the last quarter. Nuveen LLC acquired a new position in shares of Natera during the first quarter worth about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Natera by 140.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock worth $177,298,000 after acquiring an additional 732,156 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after acquiring an additional 660,538 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Natera by 8,233.5% in the first quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock worth $56,270,000 after acquiring an additional 393,149 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Price Performance

Shares of NASDAQ:NTRA traded up $0.42 on Wednesday, reaching $175.43. 618,384 shares of the company traded hands, compared to its average volume of 1,457,067. The company's 50 day moving average is $156.05 and its 200-day moving average is $154.52. The stock has a market capitalization of $24.08 billion, a PE ratio of -91.85 and a beta of 1.68. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera's revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on NTRA. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Stephens reaffirmed an "overweight" rating and set a $183.00 target price on shares of Natera in a report on Friday, August 15th. Cowen reaffirmed a "buy" rating on shares of Natera in a report on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and set a $220.00 target price (up from $210.00) on shares of Natera in a report on Monday, August 11th. Finally, Barclays reaffirmed an "overweight" rating and set a $210.00 target price (up from $190.00) on shares of Natera in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $194.00.

Insiders Place Their Bets

In other news, Director Rowan E. Chapman sold 2,750 shares of the company's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director directly owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 6,092 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $851,722.52. Following the completion of the transaction, the chief executive officer directly owned 169,400 shares in the company, valued at $23,683,814. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,423 shares of company stock valued at $8,459,656 in the last three months. Company insiders own 5.63% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.